Growth Hormone
GH Secretagogue Blend Studies
Quantity
Ships from the United States with tracking · free shipping over $200
Certificates of analysis
Each certificate covers one production run, and reports on that batch alone. Open any of them to read the laboratory report exactly as the third-party lab issued it.
Authenticity
Scan the code on the label to pull up every published certificate for that compound — the same reports the third-party laboratory issued, batch by batch. Traceable from the laboratory that tested it to your bench.
Verify a batch →Independently tested
Purity is quantified by reverse-phase HPLC and identity confirmed by mass spectrometry, by an outside laboratory rather than in-house.
A certificate for your lot
The report that ships with your order describes the batch you received — not the product line, and not a representative sample.
COA-backed replacement
If material does not match the certificate issued for its lot, we replace it or refund it. Send us the lot number and we will trace it.
Tracked dispatch
Tracking is issued when the label is created, so the shipment is traceable from the moment it leaves us.
About this compound
BLEND
This vial combines CJC-1295 with ipamorelin. The pairing is studied because the two act at different receptors: CJC-1295 mimics GHRH at the GHRH receptor, while ipamorelin binds GHS-R, the ghrelin receptor. Research on combined GHRH-analogue and secretagogue administration examines whether engaging both pathways produces a different release profile than either alone.
Full specification
How it works
The pathways CJC / IPA Blend acts on, and what each one does. Signalling described from preclinical models.
CJC-1295: GHRH Receptor Activation
The GHRH-analogue component binds GHRH-R on pituitary somatotrophs — the receptor that initiates growth hormone release under normal physiology.
Ipamorelin: Ghrelin Receptor Activation
The secretagogue component binds GHSR-1a, a distinct receptor population on the same cells. Two receptors, one cell type — which is what makes the pairing mechanistically interesting rather than redundant.
Dual-Pathway Synergistic GH Amplification
Preclinical work reports that engaging both receptors together produces a larger pulse than either does alone. The effect is described as more than additive, though the combination itself has far less published research behind it than either component.
Uses & applications
The main areas under study, and the study-reported figures behind them.
Two receptor populations on the same pituitary cells are engaged at once. That is the mechanistic claim, and it is what distinguishes the pairing from either alone.
Raun et al. 1998
Pulse shape is measured rather than total output, on the argument that release pattern carries information the amount does not.
Frieboes et al. 2004
The secretagogue here is selected for leaving cortisol and prolactin largely untouched — the off-target effects that limited earlier blends.
Raun et al. 1998
Reported as more than additive in preclinical work, though the combination has far less published research behind it than either component.
Kojima & Kangawa 2001
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
What is in the vial
This product is a mixture, so it has no single structure. It is blended from 2 compounds; the one shown here is the only one small enough for a conformer to mean anything.
Ipamorelin
Drag to rotate
101 atoms
101 atoms, 104 bonds, C38H49N9O5. Connectivity and stereochemistry from PubChem CID 9831659. The arrangement is one computed low-energy conformer, not a measured structure — a flexible peptide adopts many conformations in solution.
BLEND
Third-party verified
Every batch of CJC / IPA Blend is sent to an accredited independent laboratory before it ships. Here is what we screen for.
Quantifies purity and reports it on the lot certificate
Verifies the exact molecular identity
Lead, arsenic, cadmium & mercury
Bacterial endotoxin levels
No microbial contamination
Actual peptide mass per vial verified
FAQ
This vial combines CJC-1295 with ipamorelin. The pairing is studied because the two act at different receptors: CJC-1295 mimics GHRH at the GHRH receptor, while ipamorelin binds GHS-R, the ghrelin receptor. Research on combined GHRH-analogue and secretagogue administration examines whether engaging both pathways produces a different release profile than either alone.
Published research on CJC / IPA Blend concentrates on Dual-Pathway GH Stimulation, Physiologic Secretion Patterns, Selectivity vs GHRP-6 Blends and Complementary Signaling Pathways. Each of those areas is summarised further up this page with the citation it comes from, and the full reference list — 4 indexed publications — sits at the bottom. Study designs and concentrations vary considerably between publications, so the primary sources are worth reading directly.
The literature describes CJC / IPA Blend acting across CJC-1295: GHRH Receptor Activation, Ipamorelin: Ghrelin Receptor Activation and Dual-Pathway Synergistic GH Amplification, reported respectively as GHRH-R Pathway, GHSR-1a Pathway and Synergy. Those pathways are drawn from preclinical models rather than clinical work, and they describe what has been observed rather than a settled mechanism — the individual pathway cards above cite what each one is based on.
CJC / IPA Blend has a molecular formula of BLEND and an average mass of N/A (Blend). It ships as lyophilized powder. Those are nominal reference values for the parent compound. The identity of the specific material you receive is confirmed by mass spectrometry and reported on that lot's certificate.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. CJC / IPA Blend is water-soluble; reconstitute by directing the diluent down the vial wall rather than onto the powder, then swirl to dissolve rather than shaking. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. CJC / IPA Blend is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Cited sources
Independent published research indexed from PubMed and peer-reviewed journals — not Routine Peptides claims.
For research use only
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
